Table 5. Percentage of CITT patients in each treatment group who are classified at the 12-week outcome examination as normal/asymptomatic or improved from baseline for each outcome measure.

CI Symptom Survey *
Treatment Group	N	CISS still ≥ 16 but improved ≥ 10	CISS < 16 but improved < 10	CISS < 16 and improved ≥ 10	CISS < 16 and/or improved ≥ 10
		(A)	(B)	(C)	(A+B+C)
HBPP	53	13.2	9.4	24.5	47.1
HBCVAT+	52	15.4	5.8	17.3	38.5
OBVAT	59	17.0	6.8	49.2	72.9
OBPT	54	13.0	7.4	22.2	42.6

Near point of convergence break†,*
Treatment Group	N	Receded NPC but improved ≥ 4 cm	Normal NPC but improved < 4 cm	Normal NPC and improved ≥ 4 cm	Normal NPC and/or improved ≥ 4 cm
		(A)	(B)	(C)	(A+B+C)
HBPP	53	28.3	13.2	35.9	77.4
HBCVAT+	52	23.1	5.8	48.1	77.0
OBVAT	59	8.5	8.5	78.0	95.0
OBPT	54	33.3	5.6	20.4	59.3

Positive fusional vergence‡,*
Treatment Group	N	Insufficient PFV but improved > 10Δ	Normal PFV but improved ≤ 10Δ	Normal PFV and improved > 10Δ	Normal PFV and/or improved > 10Δ
		(A)	(B)	(C)	(A+B+C)
HBPP	53	9.4	17.0	30.2	56.6
HBCVAT+	52	7.7	7.7	44.2	59.6
OBVAT	59	3.4	10.2	69.5	83.1
OBPT	54	1.9	18.5	24.1	44.5

^†“Normal” is defined as NPC less than 6 cm; “Improved” is defined as a decrease in NPC of more than 4 cm; “Receded” is defined as NPC > 6cm

^‡“Normal” is defined as PFV greater than 15Δ and passing Sheard’s criterion; “Improved” is defined as an increase in PFV of more than 10Δ;“Insufficient” is defined as PFV ≤ 15Δ or failing Sheard’s criterion.

^*Columns A, B and C are mutually exclusive